IRMED filed another 8-K 09/03/2025, private placement ended yesterday of over 3-million shares with (3) directors, $0.013.

Depending on stock sales to fund operations.

Even with product approval, there is no guarantee of commercial success. The company must compete against existing solutions and prove its business model can be profitable.

David is still listed as an advisory board member.

https://www.otcmarkets.com/filing/html?id=187...azCb8ii9ch